Table 3.
Mixed models analysis of HLA-DR expression and LPS-induced TNF-ɑ production in septic patients who did and did not develop a secondary infection
| Secondary infection absent, n = 61 | Secondary infection present, n = 22 | p | ||
|---|---|---|---|---|
| HLA-DR expression (antibodies/cell), median (IQR) | Sample A (days 1–2)a | 6761 (4054, 12,326) n = 53 |
11,133 (4054, 16,897) n = 20 |
0.38 |
| Sample B (days 3–4)a | 8085 (4171, 15,951) n = 39 |
9438 (4008, 17,236) n = 20 |
0.79 | |
| Sample C (days 6–8)a | 9662 (6488, 17,165) n = 15 |
9722 (4852, 15,324) n = 13 |
0.77 | |
| Δ Sample A to B | 918 (-1242, 4132) | -934 (-6505, 353) | 0.054 | |
| Δ Sample A to C | 3621 (-410, 9284) | -1479 (-3382, 1662) | 0.32 | |
| LPS-induced TNF-ɑ production (pg/ml), median (IQR) | Sample A (days 1–2)a | 171 (76, 400) n = 53 |
266 (73, 523) n = 19 |
0.42 |
| Sample B (days 3–4)a | 227 (132, 341) n = 39 |
206 (46, 574) n = 17 |
0.27 | |
| Sample C (days 6–8)a | 282 (111, 427) n = 17 |
268 (52, 368) n = 10 |
0.91 | |
| Δ Sample A to B | -3 (-137, 55) | 16 (-48, 65) | 0.61 | |
| Δ Sample A to C | 7 (-140, 97) | 38 (-43, 120) | 0.54 | |
HLA-DR human leukocyte antigen-DR, LPS lipopolysaccharide, TNF-ɑ tumor necrosis factor alpha, IQR 25 %, 75 % interquartile range
aDays after sepsis diagnosis